Hannah McMurry1, Jean M G Sabile2, Benjamin Elstrott3, Boris Chobrutskiy2, Ajay Mohinani2, Sarah Patel2, Sonia Gowda2, Kylee Martens4, Joseph Shatzel5. 1. Division of Internal Medicine, Oregon Health & Science University, Portland, OR, United States of America. Electronic address: mcmurrys@ohsu.edu. 2. Division of Internal Medicine, Oregon Health & Science University, Portland, OR, United States of America. 3. Oregon Health and Science University Medical School, Portland, OR, United States of America. 4. Division of Hematology and Oncology, Oregon Health & Science University, Portland, OR, United States of America. 5. Division of Hematology and Oncology, Oregon Health & Science University, Portland, OR, United States of America; Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, United States of America.
Abstract
INTRODUCTION: Splanchnic vein thrombosis (SVT) occurs in a heterogenous group of patients secondary to a variety of risk factors including liver disease. Minimal data regarding natural history and outcomes of SVT exists to inform management decisions. As such, there is equipoise regarding the utility of anticoagulation in cirrhotic patients with SVT. We sought to identify clinical factors predictive of new or progressive thrombosis in a cohort of patients with untreated SVT. METHODS: We conducted a retrospective cohort study of cirrhotic patients over 18 years of age diagnosed with SVT at the Oregon Health & Science University from 2015 to 2020, excluding those initially treated with anticoagulation. The primary study endpoint was a composite of the following: imaging-confirmed progression of SVT, development of cavernous transformation, intestinal ischemia, portal cholangiopathy or new venous or arterial thrombosis. RESULTS: 261 patients were included in the analysis (median age 61 years, 68% male, 32% female). Forty percent of all patients experienced the primary composite endpoint. Multivariable logistic regression found that only the presence of pancreatitis or abdominal infection at diagnosis was associated with an increased likelihood of experiencing thrombus progression in patients with untreated SVT (OR 3.61, P = 0.02). There was a statistically significant overall survival difference between patients that did and did not experience the primary composite endpoint after controlling for confounding variables. (p = 0.0068). CONCLUSIONS: Overall, only the presence of pancreatitis or intrabdominal infection were found to be significantly associated with thrombotic progression, with varices identified as marginally non-significant risk factor. Notably, thrombotic progression was associated with a significant reduction in overall survival.
INTRODUCTION: Splanchnic vein thrombosis (SVT) occurs in a heterogenous group of patients secondary to a variety of risk factors including liver disease. Minimal data regarding natural history and outcomes of SVT exists to inform management decisions. As such, there is equipoise regarding the utility of anticoagulation in cirrhotic patients with SVT. We sought to identify clinical factors predictive of new or progressive thrombosis in a cohort of patients with untreated SVT. METHODS: We conducted a retrospective cohort study of cirrhotic patients over 18 years of age diagnosed with SVT at the Oregon Health & Science University from 2015 to 2020, excluding those initially treated with anticoagulation. The primary study endpoint was a composite of the following: imaging-confirmed progression of SVT, development of cavernous transformation, intestinal ischemia, portal cholangiopathy or new venous or arterial thrombosis. RESULTS: 261 patients were included in the analysis (median age 61 years, 68% male, 32% female). Forty percent of all patients experienced the primary composite endpoint. Multivariable logistic regression found that only the presence of pancreatitis or abdominal infection at diagnosis was associated with an increased likelihood of experiencing thrombus progression in patients with untreated SVT (OR 3.61, P = 0.02). There was a statistically significant overall survival difference between patients that did and did not experience the primary composite endpoint after controlling for confounding variables. (p = 0.0068). CONCLUSIONS: Overall, only the presence of pancreatitis or intrabdominal infection were found to be significantly associated with thrombotic progression, with varices identified as marginally non-significant risk factor. Notably, thrombotic progression was associated with a significant reduction in overall survival.
Authors: Douglas A Simonetto; Ashwani K Singal; Guadalupe Garcia-Tsao; Stephen H Caldwell; Joseph Ahn; Patrick S Kamath Journal: Am J Gastroenterol Date: 2020-01 Impact factor: 10.864
Authors: Noor J Sissingh; Jesse V Groen; Dylan Koole; Frederikus A Klok; Bas Boekestijn; Thomas L Bollen; Hjalmar C van Santvoort; Robert C Verdonk; Bert A Bonsing; Casper H J van Eijck; Jeanin E van Hooft; J Sven D Mieog Journal: Pancreatology Date: 2021-12-22 Impact factor: 3.996
Authors: Ana Acuna-Villaorduna; Vivy Tran; Jesus D Gonzalez-Lugo; Elham Azimi-Nekoo; Henny H Billett Journal: Thromb Res Date: 2018-12-27 Impact factor: 3.944
Authors: Mariella Faccia; Maria Elena Ainora; Francesca Romana Ponziani; Laura Riccardi; Matteo Garcovich; Antonio Gasbarrini; Maurizio Pompili; Maria Assunta Zocco Journal: World J Gastroenterol Date: 2019-08-21 Impact factor: 5.742